Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. The 5-year survival rate after curative resection is almost 80%, however, it is still less than satisfactory for metastatic CRC (mCRC). The combination approach including surgery, chemotherapy, molecular targ...

Full description

Bibliographic Details
Main Authors:	Yoshihito Kano, Mitsukuni Suenaga, Hiroyuki Uetake
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Current Oncology
Subjects:	combination therapy metastatic colorectal cancer molecular targeted therapy conversion surgery liquid biopsy <i>RAS</i>
Online Access:	https://www.mdpi.com/1718-7729/30/7/480

Similar Items

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
by: Shang-Hung Chen, et al.
Published: (2019-06-01)

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer
by: Wei Gao, et al.
Published: (2021-01-01)

Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
by: Elena Lastraioli, et al.
Published: (2023-05-01)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
by: Hiroki Osumi, et al.
Published: (2023-09-01)

Editorial: Future frontiers in the management of metastatic colorectal cancer
by: Francesco Giovinazzo, et al.
Published: (2024-10-01)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>
by: Jen-Hao Yeh, et al.
Published: (2021-12-01)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
by: Alessandro Ottaiano, et al.
Published: (2021-03-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

How opportune is multigene testing in metastatic colorectal cancer? A review
by: Cristina Orlov-Slavu, et al.
Published: (2021-10-01)

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
by: C. B. Thomsen, et al.
Published: (2018-03-01)

Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
by: Fumitaka Taniguchi, et al.
Published: (2021-12-01)

Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice
by: Saridaki Zenia, et al.
Published: (2014-12-01)

Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation
by: ZOU Jiayun, et al.
Published: (2021-08-01)

Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study
by: Xuan T, et al.
Published: (2024-03-01)

Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review
by: Ionuț Popescu, et al.
Published: (2024-04-01)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
by: Chiara Nicolazzo, et al.
Published: (2019-12-01)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
by: Liu X, et al.
Published: (2023-03-01)

Modern strategy of metastatic colorectal cancer treatment (literature review)
by: O. I. Kit, et al.
Published: (2024-09-01)

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal <i>MET</i> Amplification from Aneuploidy in Diverse Advanced Cancers
by: Yuichi Kumaki, et al.
Published: (2021-09-01)

Editorial: Recent advances in liquid biopsy in colorectal cancer
by: Claudia Cardone, et al.
Published: (2022-12-01)

BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
by: T. A. Malysheva, et al.
Published: (2015-02-01)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
by: Edoardo Isnaldi, et al.
Published: (2019-04-01)

Expert consensus on maintenance treatment for metastatic colorectal cancer in China
by: Rui-Hua Xu, et al.
Published: (2016-01-01)

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
by: Xuefeng Fang, et al.
Published: (2023-07-01)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
by: Prashanth Rawla, et al.
Published: (2019-07-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
by: Wen-Hui Xue, et al.
Published: (2023-05-01)

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
by: Rebersek Martina, et al.
Published: (2019-03-01)

THE NECESSITY OF ADVANCED RAS-MUTATIONS INVESTIGATION FOR COLORECTAL CANCER TREATMENT
by: V. A. Gorbunova
Published: (2015-02-01)

Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer
by: Menglan Zhai, et al.
Published: (2024-01-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis
by: Bradley Ashley Gue Ong, et al.
Published: (2022-04-01)

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
by: Mesti Tanja, et al.
Published: (2015-06-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
by: Ning Jia, et al.
Published: (2019-05-01)

Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor
by: Heru Sulistyo, et al.
Published: (2021-06-01)

THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE
by: M. I. Sluzhev, et al.
Published: (2021-10-01)

Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients – a single-institution experience utilising circulating tumour DNA
by: George Zarkavelis, et al.
Published: (2024-04-01)

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
by: Furong Li, et al.
Published: (2023-10-01)

Multiverse of immune microenvironment in metastatic colorectal cancer
by: Marc Van den Eynde, et al.
Published: (2020-01-01)